Report of Foreign Issuer (6-k)
September 12 2016 - 4:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of September 2016
001-37353
(Commission
File Number)
BIONDVAX
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
14
Einstein St.
Ness
Ziona
Israel
74036
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover
Form 20-F
or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If
"Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
CONTENTS
In connection with
the Extraordinary General Meeting (the “
Meeting
”) of Shareholders of BiondVax Pharmaceuticals Ltd. (the “
Company
”)
to be held on September 22, 2016, the Company received Position Notices from a number of the Company’s shareholders (the
“
Position Notices
”). In accordance with applicable laws, the Company is required to publicly disclose the Position
Notices. The Position Notices are attached hereto and incorporated by reference herein. The Company’s Board of Directors
rejects the content of the Position Notices and intends to issue a detailed response prior to the Meeting in accordance with applicable
laws.
Exhibit
Index
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Position Notice dated September 6, 2016
|
99.2
|
|
Position Notice dated September 11, 2016 (in Hebrew)
|
99.3
|
|
Position Notice dated September 12, 2016 (in Hebrew)
|
99.4
|
|
Position Notice dated September 12, 2016 (in Hebrew)
|
99.5
|
|
Position Notice dated September 11, 2016 (in Hebrew)
|
99.6
|
|
Position Notice dated September 12, 2016 (in Hebrew)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
BiondVax
Pharmaceuticals Ltd.
|
|
|
|
Date:
September 12, 2016
|
By:
|
/s/
Ron Babecoff
|
|
|
Ron
Babecoff
|
|
|
Chief
Executive Officer
|
4
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2023 to Apr 2024